Table 1.
Baseline characteristics of study participants.
| Characteristics | No. |
|---|---|
| Total patients | 30 |
|
| |
| Evaluable for response | 30 (100%) |
|
| |
| Sex | |
| Male (%) | 24 (80%) |
| Female (%) | 6 (20%) |
|
| |
| Age, years (at on-study) | |
| Median | 61 |
| Range | 48–74 |
|
| |
| ECOG performance status (%) | |
| 0 | 6 (20%) |
| 1 | 19 (63%) |
| 2 | 5 (17%) |
|
| |
| MIPI risk factors (%) | |
| Low | 12 (40%) |
| Medium | 8 (27%) |
| High | 10 (33%) |
|
| |
| Stage (%) | |
| III | 4 (13%) |
| IV | 26 (87%) |
|
| |
| Elevated LDH (%) | 20 (67%) |
|
| |
| Elevated β2m (%) | 20 (67%) |
|
| |
| Blastic morphology | 6 (20%) |
|
| |
| Ki-67 score (%)† | |
| <10% | 11 (37%) |
| 10–30% | 12 (40%) |
| >30% | 5 (17%) |
†
Ki-67 analysis not available in 2 patients.
ECOG, Eastern Cooperative Oncology Group; MIPI, Mantle Cell Lymphoma International Prognostic Index; LDH, lactate dehydrogenase.